C3N-03764
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69.0568104
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.470
- MYC_TARGETS_V2+0.420
- E2F_TARGETS+0.400
- MTORC1_SIGNALING+0.400
- MYC_TARGETS_V1+0.400
- IL6_JAK_STAT3_SIGNALING+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.350
- INFLAMMATORY_RESPONSE+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- NOTCH_SIGNALING-0.350
- WNT_BETA_CATENIN_SIGNALING-0.260
- MYOGENESIS-0.250
- PANCREAS_BETA_CELLS-0.210
- UV_RESPONSE_DN-0.160
- TGF_BETA_SIGNALING-0.150
- BILE_ACID_METABOLISM-0.140
- COAGULATION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208906 | — | — | 0.910 |
| 2 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.888 |
| 3 | faffc96a-760c-405c-9bec-d2ec116b4a1d | — | — | 0.887 |
| 4 | SRR8518156 | — | D | 0.885 |
| 5 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.885 |
| 6 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.883 |
| 7 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.882 |
| 8 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.879 |
| 9 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.876 |
| 10 | ERR2208905 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |